Outpatient Photodynamic Diagnosis–guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis–guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial

Pedersen, Gyrithe Lynghøj; Erikson, Marie Schmidt; Mogensen, Karin; Rosthøj, Susanne; Hermann, Gregers G.

doi:10.1016/j.eururo.2022.08.012

Cited by 11 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pedersen et al. [29] reported on a prospective randomised clinical trial that included 105 patients randomised to office‐based narrow‐band imaging‐guided diode laser ablation of TaLG tumours. The RFS was 57% in the office‐based group compared to 49% in the TURBT group at the 4‐month cystoscopy.…”

Section: Discussionmentioning

confidence: 99%

Long‐term outcomes and cost savings of office fulguration of papillary Ta low‐grade bladder cancer

Vitug,

Lajkosz,

Chavarriaga

et al. 2024

BJU International

View full text Add to dashboard Cite

ObjectivesRecurrent non‐muscle invasive bladder cancer (NMIBC) which carries a considerable economic burden, is primarily managed by transurethral resection of bladder tumor (TURBT). Office‐based fulguration (OF) under local anesthesia for small, recurrent, pTa low grade (LG) NMIBC is an attractive alternative to TURBT, avoiding the cost and risk of procedure and anesthesia but is not widely used. Long‐term oncological data of patients managed with OF are lacking.Material and methodsOut of 521 patients with primary TaLG, this retrospective study included 270 patients who underwent OF during follow‐up for recurrent, small, papillary low grade appearing tumours at a University Center (University Health Network, University of Toronto, Canada). We assessed the cumulative incidence of cancer specific mortality (CSM) and disease progression (to muscle‐invasive BC or metastases) as well as possible direct cost savings.ResultsIn 270 patients with recurrent TaLG treated with OF, mean age was 64.9 (SD 13.3) years, 70.8% were men and 60.3% had single tumours. The mean number of OF procedures per patient was 3.1 (SD 3.2, range 1‐22). Median follow‐up was 10.1 years (IQR 5.8−16.2). Patients also underwent a mean of 3.6 (SD 3.0) TURBTs during follow‐up in case of numerous or bulkier recurrence. 44.4% of patients never received intravesical therapy. Ten‐year incidence of CSM and progression were 0% and 3.1% (95%CI: 0.8‐5.4%), respectively. Direct cost savings in Ontario were estimated at $6994.14 per patient over the study follow up.ConclusionsThis study supports that properly selected patients with recurrent, apparent TaLG NMIBC can be safely managed with office fulguration under local anesthesia with occasional TURBT for larger or numerous recurrent tumours, without compromising long‐term oncological outcomes. This approach could generate substantial cost‐saving to health care systems, is patient‐friendly and could be adopted more widely.

show abstract

Section: Discussionmentioning

confidence: 99%

Long‐term outcomes and cost savings of office fulguration of papillary Ta low‐grade bladder cancer

Vitug,

Lajkosz,

Chavarriaga

et al. 2024

BJU International

View full text Add to dashboard Cite

show abstract

“…The primary focus in most studies on TULA has been on the oncological outcome: mortality, recurrence rate, progression-free survival time, and the cost-effectiveness [12,14,22,23]. One study focusing on treatment-related morbidity after outpatient diode laser coagulation and TURBT in the treatment of recurrent bladder tumours was conducted by Pedersen et al [26]. They found that laser treatment had fewer complications than TURBT (2% vs. 10.1%), and the impact on postoperative QoL assessed seven days after the procedure revealed lower LUTS and worry scores in favour of diode laser coagulation.…”

Section: Discussionmentioning

confidence: 99%

Patient-Reported Outcomes after Laser Ablation for Bladder Tumours Compared to Transurethral Resection—A Prospective Study

Deacon,

Nielsen,

Jensen

2024

Cancers

View full text Add to dashboard Cite

The standard procedure for diagnosis and treatment of bladder tumours, transurethral resection of bladder tumour (TURBT), is associated with a complication rate of up to 26% and potentially has severe influence on patient-reported outcomes (PRO). Outpatient transurethral laser ablation (TULA) is an emerging new modality that is less invasive with a lower risk of complications and, thereby, possibly enhanced PRO. We collected PRO following transurethral procedures in treatment of bladder tumours to evaluate any clinically relevant differences in symptoms and side effects. This prospective observational study recruited consecutive patients undergoing different bladder tumour-related transurethral procedures. Patients filled out questionnaires regarding urinary symptoms (ICIQ-LUTS), postoperative side effects, and quality of life (EQ-5D-3L) at days 1 and 14 postoperatively. In total, 108 patients participated. The most frequently reported outcomes were postoperative haematuria and pain. Patients undergoing TURBT reported longer lasting haematuria, a higher perception of pain, and a more negative impact on quality of life compared to patients undergoing TULA. TURBT-treated patients had more cases of acute urinary retention and a higher need for contacting the healthcare system. Side effects following transurethral procedures were common but generally not severe. The early symptom burden following TURBT was more extensive than that following TULA.

show abstract

“…The former is mainly located in the kidney, bladder, and prostate, and the latter is mainly situated in the kidney and ureter. About 70% of all bladder cancer diagnoses at first are nonmuscle invasive and both photodynamic diagnosis-guided laser photocoagulation of bladder cancer and transurethral laser resection of bladder cancer offer similar advantages for such patients. , Prostate cancer is one of the most frequent malignancies in males and its prevalence is becoming more common in both developed and developing countries . The current standard of care for prostate cancer involves a comprehensive approach, typically including surgical intervention. − Metastatic prostate cancer can develop into castration-resistant prostate cancer after androgen deprivation therapy and approximately 25% of such patients could further develop into lethal neuroendocrine prostate cancer .…”

Section: Introductionmentioning

confidence: 99%

“…About 70% of all bladder cancer diagnoses at first are nonmuscle invasive and both photodynamic diagnosis-guided laser photocoagulation of bladder cancer and transurethral laser resection of bladder cancer offer similar advantages for such patients. 19,20 Prostate cancer is one of the most frequent malignancies in males and its prevalence is becoming more common in both developed and developing countries. 21 The current standard of care for prostate cancer involves a comprehensive approach, typically including surgical intervention.…”

Section: ■ Introductionmentioning

confidence: 99%

Three-Dimensional Printing Creates New Trends of the Technological Revolution in Urologic Surgery

Wu,

Wang,

et al. 2024

ACS Materials Lett.

View full text Add to dashboard Cite

Additive manufacturing, commonly known as 3D printing, is a rapidly advancing technology with the capability to create intricate and precise structures. This technology has garnered significant attention in the medical field due to its ability to provide personalized diagnosis and treatment services. It finds applications in various areas, such as model printing, customized implants, and even organ printing. This review delves into the current uses of 3D printing in urology, including preoperative planning for surgeries, medical education, doctor− patient communication, and implant development. It also showcases examples of its utilization in both research and clinical settings. Moreover, the exploration of 3D printing for urethral repair and urinary organ reconstruction offers tailored solutions and the potential to replace conventional tissue engineering methods. The article provides an overview of the current applications of 3D printing technology in urology and discusses future prospects.

show abstract

Cited by 11 publications

References 14 publications

Long‐term outcomes and cost savings of office fulguration of papillary Ta low‐grade bladder cancer

Long‐term outcomes and cost savings of office fulguration of papillary Ta low‐grade bladder cancer

Patient-Reported Outcomes after Laser Ablation for Bladder Tumours Compared to Transurethral Resection—A Prospective Study

Three-Dimensional Printing Creates New Trends of the Technological Revolution in Urologic Surgery

Contact Info

Product

Resources

About